Advair vs. Pulmicort

See how Advair and Pulmicort compare on approved uses, dosing, side effects, and cost.

Key Takeaways

  • Advair combines a steroid and a long-acting bronchodilator to treat both asthma and COPD, while Pulmicort is a steroid-only inhaler approved only for asthma.

  • Both inhalers are taken twice daily for long-term control and are not meant to relieve a sudden asthma or COPD flare-up.

  • Advair carries a LABA-related warning about increased asthma-related death risk, while Pulmicort's most common side effect is nasopharyngitis, reported in up to 9.3% of users.

Advair vs. Pulmicort Drug Summary

Advair

Advair combines an inhaled corticosteroid and a long-acting bronchodilator in one twice-daily inhaler. It's approved for long-term asthma control in people 4 and older and for managing airflow obstruction and exacerbations in COPD. It is not meant for sudden asthma or COPD attacks.

Pulmicort

Pulmicort is an inhaled corticosteroid taken twice daily through a dry powder inhaler to prevent asthma symptoms over time. It's approved for maintenance asthma treatment in people 6 and older and works by reducing airway inflammation. It does not treat COPD and is not for sudden breathing emergencies.

Advair vs. Pulmicort Side Effects

Advair

Most common
Upper respiratory tract infection (up to 27%)
Headache (up to 12%)
Throat irritation (up to 6%)
Dysphonia (hoarseness) (up to 5%)

Pulmicort

Most common
Nasopharyngitis (up to 9.3%)
Nasal congestion (up to 2.7%)
Pharyngitis (up to 2.7%)
Rhinitis allergic (up to 2.2%)

Advair vs. Pulmicort Dosage

Advair

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 100 mcg/50 mcg twice daily At the start
Maximum dose 500 mcg/50 mcg twice daily If needed
Dose changes 2 increases As tolerated

Pulmicort

Dosage
Dosage Table
STAGE DOSE WHEN
Starting dose 180 mcg twice daily At the start
Maximum dose 720 mcg twice daily If needed
Dose changes 2 increases As tolerated

Advair vs. Pulmicort Indications

Advair

Advair treats both asthma and COPD by combining a steroid that reduces airway inflammation with a bronchodilator that keeps airways open. It's approved for long-term control, not for rescue use during an attack, and can also lower the frequency of COPD flare-ups.

  • Asthma maintenance in patients 4 years and older

  • COPD maintenance treatment for airflow obstruction

  • Reduces exacerbations in patients with a history of COPD flare-ups

  • Not for acute bronchospasm or status asthmaticus

Pulmicort

Pulmicort is used solely for long-term asthma control by lowering airway inflammation over time. It's FDA-approved for people 6 and older, and some doctors also prescribe it off-label for eosinophilic esophagitis. It does not treat COPD and isn't meant for sudden breathing emergencies.

  • Asthma maintenance in patients 6 years and older

  • Off-label use for eosinophilic esophagitis (not FDA-approved)

  • Not approved for children under 6 with Flexhaler

  • Not for acute bronchospasm or status asthmaticus

Advair vs. Pulmicort Pros and Cons

Advair

Advair's dual-action formula makes it a broader option, covering both asthma and COPD in one device. That versatility comes with an added LABA safety warning and a slightly more complex side-effect profile than a steroid-only inhaler.

Pros

  • Treats both asthma and COPD, unlike Pulmicort

  • Combines two mechanisms in one inhaler, simplifying treatment

  • Available as a lower-cost generic (Wixela Inhub)

  • FDA-approved specifically for reducing COPD exacerbations

Cons

  • Carries a LABA-related warning for asthma-related death risk

  • Not approved for children under 4

  • Combination therapy may be more than mild asthma requires

  • Contains two active ingredients, so more potential side effects to monitor

Pulmicort

Pulmicort's steroid-only design keeps its side-effect profile simpler and extends its approval down to younger children. The tradeoff is that it doesn't address COPD and lacks the added bronchodilator some asthma patients need.

Pros

  • Steroid-only formula may have a simpler side-effect profile

  • Approved for children as young as 6 with Flexhaler

  • Also available as a nebulized suspension for younger children

  • Sometimes used off-label for eosinophilic esophagitis

Cons

  • Not approved for COPD treatment

  • No bronchodilator, so may need to be paired with other medication

  • Flexhaler version not approved for children under 6

  • Higher reported rate of nasopharyngitis than Advair's respiratory effects

Common Symptoms and Related Diseases You Can Explore

Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.